HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Laboratories Limited

http://freestylediabetes.co.uk

Latest From Abbott Laboratories Limited

AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars

A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.

Strategy Biosimilars

AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars

A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.

Sales & Earnings Business Strategies

Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission

Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.

Drug Approval Standards Clinical Trials

Coronavirus Antigen Testing Gets Green Light In Germany

Germany is adjusting the national COVID-19 testing strategy, which from mid-October will include the use of antigen tests.

Diagnostics Germany
See All

Company Information

UsernamePublicRestriction

Register